Skip to main content
Search
Main content
medRxiv : the preprint server for health sciences
Published

African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in <em>GBA1</em>

Authors

Pilar Álvarez Jerez, Peter A Wild Crea, Daniel M Ramos, Emil K Gustavsson, Mandy Radefeldt, Mary B Makarious, Oluwadamilola O Ojo, Kimberley J Billingsley, Laksh Malik, Kensuke Daida, Sarah Bromberek, Carol Hu, Zachary Schneider, Aditya L Surapaneni, Julia Stadler, Mie Rizig, Huw R Morris, Caroline B Pantazis, Hampton L Leonard, Laurel Screven, Yue A Qi, Mike A Nalls, Sara Bandres-Ciga, John Hardy, Henry Houlden, Celeste Eng, Esteban González Burchard, Linda Kachuri, Global Parkinson’s Genetics Program (GP2), Andrew B Singleton, Steffen Fischer, Peter Bauer, Xylena Reed, Mina Ryten, Christian Beetz, Michael Ward, Njideka U Okubadejo, Cornelis Blauwendraat

Abstract

medRxiv [Preprint]. 2024 Feb 24:2024.02.20.24302827. doi: 10.1101/2024.02.20.24302827.

ABSTRACT

Recently, a novel African ancestry specific Parkinson's disease (PD) risk signal was identified at the gene encoding glucocerebrosidase (GBA1). This variant (rs3115534-G) is carried by ~50% of West African PD cases and imparts a dose-dependent increase in risk for disease. The risk variant has varied frequencies across African ancestry groups, but is almost absent in European and Asian ancestry populations. GBA1 is a gene of high clinical and therapeutic interest. Damaging bi-allelic protein-coding variants cause Gaucher disease and mono-allelic variants confer risk for PD and Dementia with Lewy Bodies, likely by reducing the function of glucocerebrosidase. Interestingly, the novel African ancestry specific GBA1 risk variant is a non-coding variant, suggesting a different mechanism of action. Using full length RNA transcript sequencing, we identified intron 8 expression in risk variant carriers (G) but not in non-variant carriers (T). Antibodies targeting the N-terminus of glucocerebrosidase showed that this intron-retained isoform is likely not protein coding and subsequent proteomics did not identify a shorter protein isoform, suggesting the disease mechanism is RNA-based. CRISPR editing of the reported index variant (rs3115534) revealed that this is the responsible sequence alteration driving production of these intron 8 containing transcripts. Follow-up analysis of this variant showed that it is in a key intronic branchpoint sequence and therefore has important implications in splicing and disease. In addition, when measuring glucocerebrosidase activity we identified a dose-dependent reduction in risk variant carriers (G). Overall, we report the functional effect of a GBA1 non-coding risk variant, which acts by interfering with the splicing of functional GBA1 transcripts, resulting in reduced protein levels and reduced glucocerebrosidase activity. This understanding reveals a novel therapeutic target in an underserved and underrepresented population.

PMID:39802803 | PMC:PMC11722498 | DOI:10.1101/2024.02.20.24302827

UK DRI Authors

John Hardy

Prof Sir John Hardy

Group Leader

Harnessing genetics to build a better understanding of dementia

Prof Sir John Hardy
Mina Ryten

Prof Mina Ryten

Centre Director

Leveraging brain transcriptomics to understand the pathophysiology of Lewy body diseases

Prof Mina Ryten